14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 121 days ( -2.91 % )
Last Price $51.99 0 %
High/ Low $51.99 - $51.99 0%
Chg 7 Days N/A $51.99 $51.99
Chg 30 Days N/A $51.99 $51.99
Chg 12 mos 115.37 % $24.14 $51.99
Trend - 3 mos N/A Width: 0.00000000 %
Trend - 12 mos 134.11 % Width: 65.79 %
Pred. range - 3 mos $51.99 - $51.99 0 % - 0 %
Pred. range - 12 mos $100.12 - $165.99 92.57 % - 219.27 %
Short MA avg 3 mos Sell Nov 30, -1 - N/A days
Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short/Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short MA avg 12 mos Sell Sep 29, 2022 - 83 days
Long MA avg 12 mos Sell Jul 29, 2022 - 126 days
Short/Long MA avg 12 mos Buy Jun 13, 2022 - 158 days
Pivot Short Sell Jan 26, 2023 - 2 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About ChemoCentryx

ChemoCentryx ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of... CCXI Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT